Search results
BMO maintains target on AstraZeneca shares, cites trial success By Investing.com
Investing.com· 2 days agoOn Wednesday, BMO Capital upheld its Outperform rating on AstraZeneca (NASDAQ:AZN) with a steady...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 7 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks via Yahoo Finance· 3 days agoAstrazeneca (AZN) closed the most recent trading day at $78.99, moving +1.24% from the previous...
Data Science Hiring Process at AstraZeneca
Analytics India Magazine· 2 days agoWith over 45 years of presence in India, British-Swedish pharmaceutical and biotechnology giant AstraZeneca has data science and AI capabilities deeply ingrained across its ...
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Forbes· 1 day agoThe American Society of Clinical Oncology held its annual conference in Chicago this past week,...
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
BioPharma Dive via Yahoo Finance· 5 days agoAstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live...
EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer
Pharmaceutical Technology via Yahoo Finance· 3 days agoThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks· 4 days agoFree Report) closed the most recent trading day at $78.99, moving +1.24% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.11%. Coming into today, shares of ...
Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
CNBC· 2 days agoAstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the...
AstraZeneca finalizes Fusion Pharmaceuticals buyout By Investing.com
Investing.com· 3 days agoThis move is aligned with AstraZeneca (NASDAQ:AZN)'s strategy to advance cancer therapy by focusing...